XML 17 R7.htm IDEA: XBRL DOCUMENT v3.7.0.1
Net Product Sales (Notes)
 3 Months Ended
Mar. 31, 2017
Revenues [Abstract]  
Product Sales and Concentration Risk [Text Block]
Product Sales
EYLEA® net product sales in the United States totaled $854.4 million and $780.9 million for the three months ended March 31, 2017 and 2016, respectively. In addition, ARCALYST® net product sales totaled $3.8 million and $3.3 million for the three months ended March 31, 2017 and 2016, respectively.
The Company had product sales to certain customers that accounted for more than 10% of total gross product revenue for each of the three months ended March 31, 2017 and 2016. Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:
 
Three Months Ended
March 31,
 
2017
 
2016
Besse Medical, a subsidiary of AmerisourceBergen Corporation
53
%
 
60
%
McKesson Corporation
27
%
 
28
%
Curascript SD Specialty Distribution, a subsidiary of Express Scripts
19
%
 
11
%

Revenue from product sales is recorded net of applicable provisions for rebates and chargebacks, distribution-related fees, and other sales-related deductions. The following table summarizes the provisions and credits/payments for these sales-related deductions during the three months ended March 31, 2017 and 2016.
 
Rebates &
Chargebacks
 
Distribution-
Related
Fees
 
Other Sales-
Related
Deductions
 
Total
Balance as of December 31, 2016
$
12,712

 
$
29,465

 
$
3,674

 
$
45,851

Provision related to current period sales
38,908

 
41,175

 
9,520

 
89,603

Credits/payments
(28,502
)
 
(42,287
)
 
(8,632
)
 
(79,421
)
Balance as of March 31, 2017
$
23,118

 
$
28,353

 
$
4,562

 
$
56,033

 
 
 
 
 
 
 
 
Balance as of December 31, 2015
$
6,419

 
$
48,313

 
$
517

 
$
55,249

Provision related to current period sales
18,885

 
35,788

 
2,910

 
57,583

Credits/payments
(17,457
)
 
(50,353
)
 
(2,557
)
 
(70,367
)
Balance as of March 31, 2016
$
7,847

 
$
33,748

 
$
870

 
$
42,465